HONG KONG DRUG LICENSING
Hong Kong Drug Licence FAQs
Search 500 Hong Kong drug licence FAQs on applications, personnel, premises, quality systems, ongoing regulation, renewals and acquisitions.
Information status: The original FAQ material dates from 2025 and is provided for topic-based reference; it does not represent an individual verification of all 500 FAQs against current rules. For application, fee, renewal, change, product or prescription requirements, please refer to the current official forms and guidance.
Official information from the Drug Office Official information from the Chinese Medicines Board
找到 50 条结果，第 1／3 页。每页显示 20 条；无需启用 JavaScript。
Q451 · 内地生产的药品如何申请香港药牌进行贴牌销售（OEM/ODM）？独立链接
For medicines manufactured in Mainland China and intended for private-label sale (OEM/ODM) in Hong Kong, first ensure that the manufacturer holds valid GMP certification and meets the relevant requirements for medicine registration under the Pharmacy and Poisons Ordinance (Cap. 138). Applicants must provide detailed product information, including manufacturing processes, quality control, test reports and stability data. The Hong Kong licence holder is also jointly liable for product quality and must ensure that imported medicines meet Hong Kong standards. A complete set of registration documents must be submitted, and the applicant must cooperate with the Drug Office’s review and on-site inspection.
Q452 · 跨境委托生产药品时，香港持牌人需要承担哪些法律责任？独立链接
Under a cross-border contract manufacturing arrangement, the Hong Kong licence holder bears ultimate responsibility for the quality, safety and compliance of the medicines it sells. The licence holder must ensure that the contract manufacturer complies with the relevant GMP standards and maintain complete production and testing records. Under the Pharmacy and Poisons Ordinance (Cap. 138), the licence holder is legally liable for any incident resulting from a medicine quality issue, including administrative penalties and civil compensation. The licence holder should therefore rigorously audit the supply chain and ensure that every step complies with regulatory requirements.
Q453 · 内地OEM厂商提供的药品批文能否直接用于香港药牌申请？独立链接
A medicine approval number (approval document) issued to a Mainland OEM manufacturer cannot directly replace a Hong Kong Certificate of Drug/Product Registration. A Hong Kong medicine licence application must include a complete set of registration information in accordance with local regulations, including evidence of quality, safety and efficacy. Although Mainland documents may be used as reference material, the Drug Office, Department of Health must still conduct an independent review and grant approval. Applicants should prepare information that meets Hong Kong standards, including the product insert, GMP certificate and test reports, and ensure compliance with the Pharmacy and Poisons Ordinance (Cap. 138).
Q454 · 跨境委托生产的药品在香港进口时有哪些合规要求？独立链接
When medicines manufactured under cross-border contract manufacturing are imported into Hong Kong, they must comply with the relevant requirements of the Pharmacy and Poisons Ordinance (Cap.138) and the Import and Export Ordinance (Cap.60). The importer must hold a valid pharmaceutical licence and ensure that the imported medicines are registered, and provide complete import declaration documents and test reports. Imported medicines must meet Hong Kong quality standards, and complete import records must be retained for inspection by the Department of Health. In addition, imported medicines may be subject to sampling tests or on-site inspections to ensure their safety and compliance.
Q455 · 香港持牌人如何监管内地OEM厂家的质量管理体系？独立链接
Hong Kong licence holders should establish a comprehensive supply chain management system and regularly audit and assess Mainland OEM manufacturers to ensure that their GMP systems meet international and Hong Kong standards. Licence holders are advised to enter into detailed quality agreements specifying each party’s responsibilities and quality standards, and to require manufacturers to provide batch production records, test reports and adverse event reports. Regular on-site audits and third-party testing are also effective oversight measures to ensure consistent product quality and compliance.
Q456 · 跨境委托生产的药品在标签及说明书上应注意哪些合规事项？独立链接
The labels and package inserts for medicines manufactured under cross-border contract manufacturing must comply with the requirements of Hong Kong’s Pharmacy and Poisons Ordinance (Cap.138), including the registration number, batch number, expiry date, ingredients, directions and dosage, and warning information. Labels should be in Chinese and English to ensure that consumers understand them. The licensee should verify that the label information provided by the OEM manufacturer is accurate and contains no misleading information. All labels and package inserts must be reviewed and approved by the Department of Health before use.
Q457 · 内地OEM生产药品出口香港时，如何确保符合香港GMP标准？独立链接
Medicines manufactured by Mainland OEMs and exported to Hong Kong must be produced in accordance with GMP standards recognised by Hong Kong. The licence holder should confirm that the manufacturer holds a valid GMP certificate and conduct regular audits. We recommend following the Drug Office’s GMP guidelines and requiring the manufacturer to establish a complete Quality Management System, covering raw material procurement, production control, quality testing and product traceability. The licence holder should retain relevant audit records as evidence of compliance and to ensure that medicine quality meets Hong Kong market requirements.
Q458 · 跨境委托生产的药品如果出现质量问题，香港持牌人应如何应对？独立链接
If a quality issue arises with a medicine manufactured under a cross-border contract manufacturing arrangement, the Hong Kong licence holder should immediately initiate a recall, notify the Department of Health and relevant regulatory departments, and cooperate with the investigation. The licence holder must trace the manufacturing and distribution records for the affected batch, assess the risk and take corresponding corrective measures. At the same time, oversight of the OEM manufacturer should be strengthened, the root cause identified and recurrence prevented. Risk alerts should be issued to consumers promptly to protect public health and the company’s reputation.
Q459 · 香港药牌申请中，内地OEM生产的药品资料应如何准备？独立链接
When applying for a Hong Kong pharmaceutical licence for medicines manufactured by an OEM in Mainland China, the product information should include detailed product descriptions, manufacturing process flow, GMP certificates, quality control standards, stability data and test reports. All information must meet the Department of Health's requirements and be submitted in Chinese or English. Applicants should ensure that the information is true and accurate, and prepare evidence of the manufacturer's qualifications and contract documents to demonstrate the contract manufacturing relationship. Thorough preparation of the information is key to a successful application.
Q460 · 跨境委托生产药品的进出口流程中，如何确保合规与效率？独立链接
The import and export process for medicines manufactured under cross-border contract manufacturing involves regulation by several departments. Applicants should ensure that all relevant licences are in place, including Hong Kong pharmaceutical licences and import and export licences. For imports, prepare complete declaration documents in advance and ensure that product registration information, test reports, transport documents and other materials meet the requirements. We recommend establishing an efficient supply chain management system and maintaining good communication with logistics providers, Customs and regulatory authorities, so that inspections and requests for additional information can be handled promptly and customs clearance can be completed both compliantly and efficiently.
Q461 · 香港药品注册申请流程的主要步骤有哪些？独立链接
The medicine registration process in Hong Kong mainly comprises the following steps: first, prepare a complete application, including the medicine package insert and quality and safety information; next, submit the registration application to the Drug Office, Department of Health, and pay the relevant fees; the Drug Office will then review the information and may conduct an on-site inspection; finally, if the requirements of the Pharmacy and Poisons Ordinance (Cap.138) are met, a pharmaceutical product registration number (such as HK-XXXXX) will be issued, allowing the medicine to be sold in Hong Kong. The process usually takes several months. Applicants should ensure that the information is accurate and complete to avoid delays.
Q462 · 香港药牌（HK-XXXXX）编号是如何分配和管理的？独立链接
The Drug Office, Department of Health, allocates Hong Kong pharmaceutical licence numbers centrally. Each approved registered medicine receives a unique number to identify it and regulate its sale on the market. The “HK-” prefix denotes Hong Kong, and the following digits are generated in registration date order. The licence number must be clearly displayed on the medicine packaging and package insert to enable tracking and verification. This numbering system helps regulators monitor the distribution and safety of medicines.
Q463 · 香港药品注册与内地药品注册有哪些核心差异？独立链接
Hong Kong medicine registration focuses on medicine quality, safety and labelling compliance. The process is relatively straightforward and does not require clinical trial data to have been generated locally. By contrast, registration of medicines in Mainland China under the Measures for the Administration of Drug Registration is more complex, requiring rigorous clinical trials and consistency evaluations, with longer approval times. Hong Kong focuses on regulation under the Pharmacy and Poisons Ordinance (Cap.138), with an emphasis on post-market oversight, whereas Mainland China has strict pre-market approval by the National Medical Products Administration. The requirements for registration information and approval procedures differ significantly between the two jurisdictions, so businesses need to prepare accordingly.
Q464 · 申请香港药牌时，是否需要提交临床试验数据？独立链接
Hong Kong medicine registration does not usually require applicants to submit local clinical trial data, but sufficient international clinical research information must be provided to demonstrate the medicine’s safety and efficacy. If the clinical data submitted comes from internationally recognised regulatory authorities or literature, the Drug Office will accept it. For innovative medicines or special indications, the Drug Office may also request supplementary information. Overall, Hong Kong’s registration process places greater emphasis on international data supporting medicine quality and safety.
Q465 · 香港药牌申请对药品标签和说明书有哪些具体要求？独立链接
Hong Kong requires medicine labels and package inserts to be presented bilingually in Chinese and English. They should include the medicine name, pharmaceutical product registration number (HK-XXXXX), ingredients, directions and dosage, indications, adverse reactions, storage conditions and manufacturer information, among other details. Labels must comply with the Department of Health’s format requirements to ensure that consumers can clearly understand the information. In addition, all promotional materials must not contain false or misleading statements and must comply with the relevant provisions of the Pharmacy and Poisons Ordinance.
Q466 · 在香港申请药牌时，如何处理与内地已有注册的药品数据差异？独立链接
Hong Kong pharmaceutical licence applications may use existing registration data from Mainland China, but applicants must ensure that the data meets Hong Kong regulatory requirements, including quality standards and safety assessments. As standards differ between the two jurisdictions, some data may need to be adjusted or supplemented, for example, ingredient specifications, excipients and packaging information. Applicants are advised to prepare supplementary information for the Hong Kong market and communicate promptly with the Drug Office, Department of Health, to ensure that the submission is complete and complies with local requirements.
Q467 · 香港药牌审批时间通常需要多久？独立链接
In general, the approval process for a Hong Kong pharmaceutical licence takes around 3 to 6 months, depending on the completeness and complexity of the application. If the documents are complete and meet the requirements, approval may be relatively quick; if further information is needed or an on-site inspection is conducted, the process may take longer. Compared with pharmaceutical registration in Mainland China, the Hong Kong process is simpler, but a reasonable amount of time should still be allowed. Applicants should prepare in advance and cooperate fully with the Drug Office’s review requirements.
Q468 · 跨境医药企业在香港申请药牌时需要具备哪些资格或条件？独立链接
Cross-border pharmaceutical companies applying for Hong Kong pharmaceutical licences must be legally registered in Hong Kong or overseas, have a good business record and comply with the Pharmacy and Poisons Ordinance (Cap.138). They must appoint a local representative in Hong Kong (such as an agent) to liaise with the Drug Office, Department of Health, and ensure that information is complete and updated promptly. They must also have a robust pharmaceutical Quality Management System and post-market tracking mechanism to ensure the safe distribution of medicines.
Q469 · 申请香港药牌时如何处理药品成分与内地标准不一致的情况？独立链接
If the ingredients of a medicine registered in Hong Kong differ from mainland standards, the applicant must submit detailed ingredient information and a safety assessment report to demonstrate that the formulation complies with Hong Kong standards and is safe and effective. Labelling information must be adjusted where necessary to reflect the actual ingredients. The Drug Office will assess the application based on the actual risks and scientific evidence to ensure public safety in the use of medicines. It is advisable to compare the ingredients and prepare comprehensive technical information before applying.
Q470 · 香港药牌注册后，药品的变更申报有哪些要求？独立链接
After a medicine is registered in Hong Kong, if there are significant changes to its ingredients, manufacturing process, packaging or labelling, the applicant must submit a change application to the Drug Office, Department of Health, and obtain approval before implementing the changes. The change submission must include an explanation of the changes and relevant supporting information to ensure that they do not affect the medicine’s quality or safety. Minor changes should also be recorded and documented. Failure to notify changes as required may be regarded as an offence.